uniQure (NASDAQ:QURE) Receives Average Recommendation of “Moderate Buy” from Analysts

uniQure (NASDAQ:QURE) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $38.89.

QURE has been the subject of a number of research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Wells Fargo & Company dropped their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Tuesday, March 11th. Finally, Stifel Nicolaus increased their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th.

Insider Buying and Selling

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new position in shares of uniQure in the 4th quarter valued at approximately $38,410,000. Franklin Resources Inc. raised its position in uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after purchasing an additional 494,726 shares in the last quarter. Point72 Asset Management L.P. raised its position in uniQure by 81.3% during the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after purchasing an additional 794,459 shares in the last quarter. Integral Health Asset Management LLC lifted its stake in uniQure by 175.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP boosted its holdings in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after purchasing an additional 893,625 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of QURE stock opened at $12.47 on Tuesday. The company has a fifty day moving average price of $13.77 and a two-hundred day moving average price of $10.79. uniQure has a one year low of $3.73 and a one year high of $19.18. The stock has a market cap of $674.34 million, a P/E ratio of -2.51 and a beta of 0.36. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.